Simone Veronese1, G Gallo1, A Valle1, C Cugno1, A Chiò2, A Calvo2, P Cavalla2, M Zibetti2, C Rivoiro3, D J Oliver4. 1. Fondazione Assistenza e Ricerca in Oncologia (FARO) Onlus, Turin, Italy. 2. Department of Neuroscience, ALS Centre, University of Turin, Turin, Italy. 3. Agenzia Regionale Servizi Sanitari Piemonte ARESS Piemonte, Turin, Italy. 4. Centre for Professional Practice, University of Kent, Chatham, UK.
Abstract
BACKGROUND: This study analysed the impact on palliative care outcomes of a new specialist palliative care service for patients severely affected by amyotrophic lateral sclerosis (ALS/MND), multiple sclerosis, Parkinson's disease and related disorders (multiple system atrophy progressive supranuclear palsy, MSA-PSP). METHODS: The design followed the Medical Research Council Framework for the evaluation of complex interventions. A phase II randomised controlled trial (RCT) was undertaken comparing an immediate referral to the service (FT, fast track) to a 16-week wait (standard track (ST), standard best practice) using a parallel arm design. The main outcome measures were Quality of Life (measured with Schedule for the Evaluation of Individual Quality of Life Direct Weight, SEIQoL-DW) and burden of the carers (Caregivers Burden Inventory, CBI), with secondary outcomes of symptoms, psychosocial and spiritual issues. RESULTS:50 patients severely affected by neurodegenerative conditions and their informal family carers were randomised: 25 FT, 25 ST. At baseline (T0), there were no differences between groups. 4 patients died during the follow-up (2 FT, 2 ST) and 2 FT patients dropped out before the end of the study. After 16 weeks (T1), FT participants scored significant improvement in the SEIQoL-DW index, pain dyspnoea sleep disturbance and bowel symptoms. CONCLUSIONS: This exploratory RCT provides evidence that no harm was experienced by SPCS for patients severely affected by neurodegenerative disorders. There was an improvement in quality of life and physical symptoms for neurological patients in palliative care. Caregiver burden was not affected by the service. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
BACKGROUND: This study analysed the impact on palliative care outcomes of a new specialist palliative care service for patients severely affected by amyotrophic lateral sclerosis (ALS/MND), multiple sclerosis, Parkinson's disease and related disorders (multiple system atrophy progressive supranuclear palsy, MSA-PSP). METHODS: The design followed the Medical Research Council Framework for the evaluation of complex interventions. A phase II randomised controlled trial (RCT) was undertaken comparing an immediate referral to the service (FT, fast track) to a 16-week wait (standard track (ST), standard best practice) using a parallel arm design. The main outcome measures were Quality of Life (measured with Schedule for the Evaluation of Individual Quality of Life Direct Weight, SEIQoL-DW) and burden of the carers (Caregivers Burden Inventory, CBI), with secondary outcomes of symptoms, psychosocial and spiritual issues. RESULTS: 50 patients severely affected by neurodegenerative conditions and their informal family carers were randomised: 25 FT, 25 ST. At baseline (T0), there were no differences between groups. 4 patients died during the follow-up (2 FT, 2 ST) and 2 FT patients dropped out before the end of the study. After 16 weeks (T1), FT participants scored significant improvement in the SEIQoL-DW index, pain dyspnoea sleep disturbance and bowel symptoms. CONCLUSIONS: This exploratory RCT provides evidence that no harm was experienced by SPCS for patients severely affected by neurodegenerative disorders. There was an improvement in quality of life and physical symptoms for neurologicalpatients in palliative care. Caregiver burden was not affected by the service. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Claire J Creutzfeldt; Benzi Kluger; Adam G Kelly; Monica Lemmon; David Y Hwang; Nicholas B Galifianakis; Alan Carver; Maya Katz; J Randall Curtis; Robert G Holloway Journal: Neurology Date: 2018-06-27 Impact factor: 9.910
Authors: Kathleen E Bickel; Cari Levy; Edward R MacPhee; Keri Brenner; Jennifer S Temel; Joanna J Arch; Joseph A Greer Journal: J Pain Symptom Manage Date: 2020-05-21 Impact factor: 3.612
Authors: Carolina Oc Latorraca; Ana Luiza C Martimbianco; Daniela V Pachito; Maria Regina Torloni; Rafael L Pacheco; Juliana Gomes Pereira; Rachel Riera Journal: Cochrane Database Syst Rev Date: 2019-10-22
Authors: Anastasia Vishnevetsky; Carla Zapata Del Mar; Juan Luis Cam; Mario Cornejo-Olivas; Claire J Creutzfeldt Journal: J Palliat Med Date: 2018-12-08 Impact factor: 2.947
Authors: A M Giovannetti; E Pietrolongo; A Giordano; V Cimino; A Campanella; G Morone; A Fusco; A Lugaresi; P Confalonieri; F Patti; M G Grasso; M Ponzio; S Veronese; A Solari Journal: Qual Life Res Date: 2016-04-28 Impact factor: 4.147
Authors: Tomi Kuusimäki; Samu Kurki; Jussi O T Sipilä; Heli Salminen-Mankonen; Olli Carpén; Valtteri Kaasinen Journal: Mov Disord Clin Pract Date: 2020-04-27